The invention relates a pharmaceutical composition comprising a
combination of: (i) the AT 1-antagonist vaisertan or a pharmaceutically
acceptable salt thereof; and (ii) a NEP inhibitor or a pharmaceutically
acceptable salt thereof and optionally a pharmaceutically acceptable
carrier and to a method for the treatment or prevention of a condition or
diseaseselected from the group consisting of hypertension, heart failure,
such as (acute and chronic) congestive heart failure, left ventricular
dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy,
supraventricular and ventricular arrhythmias, atrial fibrillation, atrial
flutter, detrimental vascular remodeling, myocardial infarction and its
sequelae, atherosclerosis, angina (whether unstable or stable), renal
insufficiency (diabetic and non-diabetic), heart failure, angina
pectoris, diabetes, secondary aldosteronism, primary and secondary
pulmonary hypertension, renal failure conditions, such as diabetic
nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis,
proteinuria of primary renal disease, and also renal vascular
hypertension, diabetic retinopathy, the management of other vascular
disorders, such as migraine, peripheral vascular disease, Raynaud's
disease, luminal hyperplasia, cognitive dysfunction, such as Alzheimer's,
glaucoma and stroke, comprising administering a therapeutically effective
amount of the pharmaceutical composition to a mammal in need thereof.